Grover S A, Coupal L, Fahkry R, Suissa S
Centre for Cardiovascular Risk Assessment, Montreal General Hospital, Que.
CMAJ. 1991 Jan 15;144(2):161-8.
To determine the cost of screening all Canadians aged 30 years or more without coronary heart disease (CHD) for hypercholesterolemia.
The expected results of initial screening of the serum cholesterol level were estimated on the basis of 1986 Canadian census data and the 1978 Canada Health Survey. The results of repeat testing were estimated on the basis of data from the Lipid Research Clinics Prevalence Study. Lipid profile results were extrapolated from tests at the Montreal General Hospital's clinical chemistry laboratory. Laboratory costs and primary care practitioner costs were provided by the Canadian Society of Clinical Chemists and provincial fee schedules respectively.
Among 12,479,356 Canadians free of CHD 48.7% would be identified as being at high risk, 4.8% would be identified as being at moderate risk, and 46.6% would be reassured that their lipid risk for CHD was low. The total cost of implementing the program in the first year would be $432 million to $561 million ($325 million for laboratory tests and $107 million to $236 million for visits to primary care practitioners).
The substantial cost of implementing a nationwide screening program must be weighed against the expected benefits to ensure that the final result is both practical and economically feasible.
确定对所有30岁及以上无冠心病(CHD)的加拿大人进行高胆固醇血症筛查的成本。
血清胆固醇水平初始筛查的预期结果是根据1986年加拿大人口普查数据和1978年加拿大健康调查估算得出的。重复检测的结果是根据脂质研究诊所患病率研究的数据估算得出的。血脂谱结果是从蒙特利尔综合医院临床化学实验室的检测结果推断而来的。实验室成本和初级保健医生成本分别由加拿大临床化学家协会和省级收费标准提供。
在12479356名无冠心病的加拿大人中,48.7%将被确定为高危人群,4.8%将被确定为中度风险人群,46.6%将放心地得知其患冠心病的脂质风险较低。该项目第一年实施的总成本将在4.32亿加元至5.61亿加元之间(实验室检测费用为3.25亿加元,初级保健医生诊疗费用为1.07亿加元至2.36亿加元)。
实施全国性筛查项目的巨大成本必须与预期收益相权衡,以确保最终结果既切实可行又在经济上可行。